A BioMarin spokesperson said: 'Brineura was provided as part of an Early Access Program which, given the rapid onset and progression of the disease, was set up by BioMarin to manage the delay between product approval and the reimbursement of the medicine in England.
Okhulumela i-BioMarin uthe: 'u-Brineura wahlinzekwa njengengxenye yoHlelo Lokusheshe Kungen i-Early Access Program okuthe ngokubona isifo sibhebhetheka ngamandla, i-BioMarin yalusungula ukuze kuhekanwe nokubambezeleka okungenzeka Phakathi kokugunyazwa komkhiqizo nokukhokhelwa kwekhambi Engilandi.